Loading...
XSTO
DIABIO
Market cap1mUSD
Apr 07, Last price  
0.01SEK
1D
-7.14%
1Q
-24.86%
IPO
-99.93%
Name

Diagonal Bio AB

Chart & Performance

D1W1MN
P/E
P/S
686.72
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
23k
-88.67%
20,310407,000203,00023,000
Net income
-12m
L-27.75%
-583,360-11,663,000-16,164,000-11,678,000
CFO
-5m
L-66.84%
226,667-10,943,000-15,773,000-5,231,000

Profile

Diagonal Bio AB operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was founded in 2020 and is headquartered in Lund, Sweden.
IPO date
Jul 16, 2021
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
23
-88.67%
203
-50.12%
Cost of revenue
(3,110)
(1,851)
Unusual Expense (Income)
NOPBT
3,133
2,054
NOPBT Margin
13,621.74%
1,011.82%
Operating Taxes
(15,163)
Tax Rate
NOPAT
3,133
17,217
Net income
(11,678)
-27.75%
(16,164)
38.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,675
13,548
BB yield
-13.01%
-129.65%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1,000
(2)
Net debt
(2,972)
(13,585)
Cash flow
Cash from operating activities
(5,231)
(15,773)
CAPEX
(4,246)
(4,956)
Cash from investing activities
(4,246)
(4,956)
Cash from financing activities
(1,136)
13,548
FCF
5,638
17,217
Balance
Cash
2,972
13,585
Long term investments
Excess cash
2,971
13,575
Stockholders' equity
(59,756)
(24,935)
Invested Capital
81,004
56,183
ROIC
4.57%
34.03%
ROCE
14.74%
6.57%
EV
Common stock shares outstanding
36,478
9,500
Price
0.35
-67.91%
1.10
-87.72%
Market cap
12,877
23.23%
10,450
-90.02%
EV
9,905
(3,135)
EBITDA
3,136
2,054
EV/EBITDA
3.16
Interest
206
1,001
Interest/NOPBT
6.58%
48.73%